Source:http://linkedlifedata.com/resource/pubmed/id/15620827
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2004-12-28
|
| pubmed:abstractText |
Carbapenem resistance among Pseudomonas aeruginosa and Acinetobacter spp. is becoming a critical therapeutic problem worldwide. The SENTRY Antimicrobial Surveillance Program monitors pathogen frequency and antimicrobial resistance patterns of nosocomial and community-acquired infections through sentinel hospitals on five continents. Pseudomonas spp. and Acinetobacter spp. strains resistant to imipenem (MIC, >/=16 mg/l), meropenem (MIC, >/=16 mg/l), and ceftazidime (MIC, >/=32 mg/l) collected from January 2001 to December 2003 were routinely screened for antimicrobial resistance genes. Resistant isolates were initially tested for metallo-beta-lactamase (MbetaL) production by phenotypic tests (disk approximation or MbetaL Etest strip) and then characterization of the MbetaL (hydrolysis assays, PCR for bla(IMP), bla(VIM), bla(SPM), gene sequencing). Eighty-nine isolates (33 Acinetobacter spp., 54 Pseudomonas aeruginosa, and 2 P. fluorescens) had positive phenotypic screening tests. Among those, 34 isolates producing MbetaL were identified, including 7 Acinetobacter spp., 25 P. aeruginosa and 2 P. fluorescens. The MbetaLs identified were IMP-1, VIM-2 and two newly described enzymes: SPM-1 and IMP-16. The greatest concentration of MbetaL strains was in Brazil, where imipenem-resistant P. aeruginosa increased significantly in the time period evaluated by the SENTRY Program. MbetaL-producing P. aeruginosa was detected in São Paulo (SPM-1) and Brasilia (SPM-1 and IMP-16), Brazil and Caracas, Venezuela (VIM-2); while MbetaL-producing Acinetobacter spp. isolates were detected in São Paulo, Brazil (IMP-1). P. fluorescens isolates producing IMP-1 and VIM-2 were detected in São Paulo, Brazil and Santiago, Chile, respectively. The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0924-8579
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
57-61
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15620827-Acinetobacter,
pubmed-meshheading:15620827-Acinetobacter Infections,
pubmed-meshheading:15620827-Anti-Bacterial Agents,
pubmed-meshheading:15620827-Carbapenems,
pubmed-meshheading:15620827-Humans,
pubmed-meshheading:15620827-Imipenem,
pubmed-meshheading:15620827-Latin America,
pubmed-meshheading:15620827-Microbial Sensitivity Tests,
pubmed-meshheading:15620827-Pseudomonas Infections,
pubmed-meshheading:15620827-Pseudomonas aeruginosa,
pubmed-meshheading:15620827-Pseudomonas fluorescens,
pubmed-meshheading:15620827-Ribotyping,
pubmed-meshheading:15620827-Sentinel Surveillance,
pubmed-meshheading:15620827-beta-Lactam Resistance,
pubmed-meshheading:15620827-beta-Lactamases
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program.
|
| pubmed:affiliation |
The JONES Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, USA. helio-sader@jmilabs.com
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|